HLA-A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant

American Journal of Surgical Pathology

Volumn 31, Issue 1, 2007, Pages 76-84

  Benevolo, Maria ^a   Mottolese, Marcella ^a   Piperno, Giulia ^a   Sperduti, Isabella ^b   Cione, Antonio ^a   Sibilio, Leonardo ^a   Martayan, Aline ^a   Donnorso, Raffaele Perrone ^a   Cosimelli, Maurizio ^a   Giacomini, Patrizio ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Biostatistics Unit   (Italy)

Author keywords

B; C; Colon carcinoma; HLA A; Prognosis; Tumor immune evasion; Tumor immune surveillance

Indexed keywords

FORMALDEHYDE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLON CARCINOMA; COLON MUCOSA; DISEASE FREE SURVIVAL; DOWN REGULATION; EVALUATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; NEOPLASM; PHENOTYPE; PROGNOSIS; STAINING; TUMOR CELL; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLON; COLORECTAL NEOPLASMS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33845929964     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000213343.55605.b9     Document Type: Article

References (38)

1. Sobin LH, Wittekind CH, eds. TNM Classification of Malignant Tumors. 6th ed. Hoboken, NJ: John Wiley & Sons; 2002.
2. Buglioni S, D'Agnano I, Cosimelli M, et al. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer. 1999;84:545-552.
3. Concha A, Cabrera T, Ruiz-Cabello F, et al. Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer. 1991;6:146-154
4. Cordon-Cardo C, Fuks Z, Drobnjak M, et al. Expression of HLAA, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res. 1991;51:6372-6380.
5. Coulie PG, van der Bruggen P. T-cell responses of vaccinated cancer patients. Curr Opin Immunol. 2003;15:131-137.
6. Doucey MA, Scarpellino L, Zimmer J, et al. Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat Immunol. 2004;5:328-336.
7. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
8. 2m: distribution in normal tissues and neoplastic lesions of non-lymphoid origin and IFN-γ responsiveness. Tissue Antigens. 1997;50:555-566.
9. Giacomini P, Giorda E, Fraioli R, et al. Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines. Cancer Res. 1999;59:2657-2667.
10. Giorda E, Sibilio L, Martayan A, et al. The antigen processing machinery of Human Leukocyte Antigens: linked patterns of gene expression in neoplastic cells. Cancer Res. 2003;63:4119-4127.
11. Goepel JR, Rees RC, Rogers K, et al. Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br J Cancer. 1991;64:880-883.
12. Gudmundsdóttir I, Jónasson JG, Sigurdsson H, et al. Altered expression of HLA class I antigens in breast cancer: association with prognosis. Int J Cancer. 2000;89:500-505.
13. Held W, Coudert JD, Zimmer J. The NK cell receptor repertoire: formation, adaptation and exploitation. Curr Opin Immunol. 2003;15:233-237.
14. Kaklamanis L, Leek R, Koukourakis M, et al. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 1995;55:5191-5194.
15. Kamarashev J, Ferrone S, Seifert B, et al. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer. 2001;95:23-28.
16. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436:709-713.
17. Korkolopoulou P, Kaklamanis L, Pezzella F, et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer. 1996;73:148-153.
18. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
19. Ljunggren H-G, Kärre K. Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression: opposing influences of T cells and natural killer mediated resistance? J Immunogenet. 1986;13:141-143.
20. Luboldt H-J, Kubens BS, Rübben H, et al. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res. 1996;56:826-830.
21. Maiorana A, Cesinaro AM, Fano RA, et al. Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases. Clin Exp Metastasis. 1995;13:43-48.
22. Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181-273.
23. Menon AG, Morreau H, Tollenaar RA, et al. Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest. 2002;82:1725-1733.
24. Mischiati C, Natali PG, Sereni A, et al. cDNA array profiling of melanomas and paired melanocyte cultures. J Cell Physiol. 2006;207:697-705.
25. Möller P, Koretz K, Schlag P, et al. Frequency of abnormal expression of HLA-A, B, C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence. Int J Cancer. 1991;6:155-162.
26. Möller P, Mattfeldt T, Gross C, et al. Expression of HLA-A, -B, -DR, -DP, -DQ, and of HLA-D-associated invariant chain (Ii) in non-neoplastic mammary epithelium, fibroadenoma, adenoma, and carcinoma of the breast. Am J Pathol. 1989;135:73-83.
27. Möller P, Momburg F, Koretz K, et al. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res. 1991;51:729-736.
28. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol. 1998;16:323-358.
29. Pende D, Accame L, Pareti L, et al. The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur J Immunol. 1998;28:2384-2394.
30. Raulet DH. Development and tolerance of natural killer cells. Curr Opin Immunol. 1999;11:129-134.
31. Redondo M, Concha A, Oldiviela R, et al. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res. 1991;51:4948-4954.
32. Ruiter DJ, Mattijssen V, Broecker EB, et al. MHC antigens in human melanomas. Semin Cancer Biol. 1991;2:35-45.
33. 2- microglobulin. Hum Immunol. 1996;46:69-81.
34. Shilling HG, Young N, Guethlein LA, et al. Genetic control of human NK cell repertoire. J Immunol. 2002;169:239-247.
35. Stam NJ, Vroom ThM, Peters PJ, et al. HLA-A and HLA-B-specific monoclonal antibodies reactive with free heavy chains in Western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryoimmuno-electron microscopy. Int Immunol. 1990;2:113-125.
36. van den Ingh HF, Ruiter DJ, Griffioen G, et al. HLA antigens in colorectal tumours. Low expression of HLA class I antigens in mucinous colorectal carcinomas. Br J Cancer. 1987;55:125-130.
37. Watson NF, Ramage JM, Madjd Z, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer. 2005;118:6-10.
38. 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas. Br J Cancer. 1990;62:289-295.